Coronary Artery Disease Clinical Trial
Official title:
A Prospective, Multicenter, Randomized Comparative Evaluation of BuMA Supreme Stent and of Xience Stent in Terms of the Extent of Neointimal Formation at 1 Month and 2 Months Via OCT After Implantation in High Bleeding Risk CAD Patients(PIONEER-II OCT Study)
Verified date | October 2021 |
Source | Sino Medical Sciences Technology Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is a comparative evaluation of BuMA Supreme™ stent and of Xience V/Prime stent in terms of the extent of neointima formation at 1 or 2 months after implanting in relatively high bleeding risk patients with coronary artery disease using OCT.
Status | Completed |
Enrollment | 82 |
Est. completion date | March 3, 2021 |
Est. primary completion date | May 11, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. 18 to 85 years. 2. Evidence of myocardial ischemia without raised troponin (e.g. stable or unstable angina, silent ischemia demonstrated by positive territorial functional study). 3. Any one or more situation listed below can be considered the patient at high bleeding risk by the doctor: - Adjunctive oral anticoagulation treatment planned to continue after PCI; - Baseline Hb =11 g/dl (or anemia requiring TF during the prior 4 weeks); - Any prior intra-cerebral bleed at any time; - Any stroke during the past year; - Hospital admission for bleeding during the prior 12 months; - Non-skin cancer diagnosed or treated = 3 years; - Planned daily NSAID (other than aspirin) or steroids for = 30 days after PCI; - Planned major surgery (within 1 year); - Renal failure (calculated creatinine clearance = 40 ml/min); - Thrombocytopenia (= 100,000/mm3); - Severe chronic liver disease (variceal hemorrhage, ascites, hepatic encephalopathy or jaundice); - Expected non-compliance to prolonged DAPT for other medical (nonfinancial)reasons ; - NSAID, Non-steroidal anti-inflammatory drug; TF, blood transfusion. 4. The patient has a planned intervention of up to two de novo lesions, in different epicardial vessels. 5. Lesion(s) must have a visually estimated diameter stenosis of =70% and <100%. 6. Reference Vessel Diameter (RVD) must be between 2.5- 4.0mm, and the vessel length must be no more than 40 mm. 7. Written informed consent. 8. The patient and the patient's physician agree to the follow-up visits including angiographic follow-up and OCT controls at 1 or 2 month. Exclusion Criteria: 1. Evidence of ongoing acute myocardial infarction in ECG prior to procedure. 2. Left ventricular ejection fraction (LVEF) <30%. 3. The patient is a recipient of a heart transplant. 4. Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel and ticlopidine), sirolimus or stainless steel, cobalt metal or sensitivity to contrast media, which cannot be adequately pre-medicated. 5. Other medical illness (e.g. skin cancer diagnosed or treated > 3 years, neurological deficiency) or known history of substance abuse (alcohol etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy. 6. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 7. Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter = 2.5mm and bypass lesion 8. Patients expected not to comply with 1 month DAPT; 9. Compliance with long-term single anti-platelet therapy unlikely; 10. Active bleeding at the time of inclusion; 11. Patients requiring a planned staged PCI procedure more than one week after theindex procedure; 12. Procedure planned to require non-study stents, or stand alone POBA or stand-alone atherectomy; 13. Reference vessel diameter <2.25 - >4.0mm, vessel length >40mm; 14. Cardiogenic shock; 15. Participation in another clinical trial (12 months after index procedure). 16. Those who is not suitable to attend this trial after the evaluation by the doctor. OCT exclusion criteria - Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter - Total occlusion or thrombolysis in myocardial infarction(TIMI) flow 0, prior to wire crossing. |
Country | Name | City | State |
---|---|---|---|
China | The PLA General Hospital | BeiJing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Sino Medical Sciences Technology Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The percentage of the struts' neointimal coverage (%) at 1 or 2 months follow-up by OCT assessment. | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Neointimal hyperplasia area/volume | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Mean/Minimal Stent diameter/area/volume | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Mean/Minimal Lumen diameter/area/volume | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Mean/maximal thickness of the struts coverage | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Incomplete strut apposition | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Minimal Lumen Diameter(MLD) and Diameter stenosis percentage(%DS) post procedure and at 3 months | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 months | |
Secondary | Late Lumen Loss | 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group | 1 or 2 month | |
Secondary | Binary Restenosis (DS =50%) | All measurements will be made of the in-stent, in-segment, proximal and distal stent margins. | 1 or 2 months | |
Secondary | Acute success rate | It includes the device success,lesion success and procedural success. | up to 7 days | |
Secondary | Device-oriented Composite Endpoints and its individual components | Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, Myocardial Infarction(MI) not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization. | 1 or 2, 3, 6 months, 1 year, 2 years | |
Secondary | Stent thrombosis according to the ARC definitions | Definite and probable stent thrombosis during acute, subacute, later and very late phase. | 1 or 2, 3, 6 months, 1 year, 2 years | |
Secondary | bleeding events | 1 or 2, 3, 6 months, 1 year, 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |